Cadrenal Therapeutics Acquires Tecarfarin from Horizon
Cadrenal Therapeutics Acquires Tecarfarin from Horizon PONTE VEDRA, Florida – April 1, 2022 – Cadrenal Therapeutics, Inc. (“Cadrenal”) has acquired the rights to tecarfarin from Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, […]
Atrial fibrillation in patients with end‐stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation
The aim of this narrative review is to examine and discuss current evidence on AF, stroke occurrence, and prevention in patients with ESRD on HD as well as the opportunities of DOAC use in this clinically challenging setting. Authors: Oliver Königsbrügge, MD, PhD and Cihan Ay, MD Abstract: Atrial fibrillation (AF) is a frequent comorbid condition in […]
